Literature DB >> 26224625

Comment on: Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.

Mireille Crampe1, Stephen E Langabeer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26224625     DOI： 10.1007/s40291-015-0151-6

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN： 1177-1062            Impact factor:   4.074


× No keyword cloud information.
  10 in total

1.  Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.

Authors:  Elia Mattarucchi; Francesco Pallotti; Rosario Casalone
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

2.  Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR.

Authors:  Lawrence J Jennings; David George; Juliann Czech; Min Yu; Loren Joseph
Journal:  J Mol Diagn       Date:  2013-12-31       Impact factor: 5.568

3.  Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease.

Authors:  Lawrence J Jennings; Frederick A Smith; Kevin C Halling; Diane L Persons; Suzanne Kamel-Reid
Journal:  Arch Pathol Lab Med       Date:  2012-01       Impact factor: 5.534

4.  Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.

Authors:  Letizia Foroni; Gill Wilson; Gareth Gerrard; Joanne Mason; David Grimwade; Helen E White; David Gonzalez de Castro; Stephen Austin; Abida Awan; Emma Burt; Tim Clench; Joanna Farruggia; Jeremy Hancock; Alexandra E Irvine; Aytug Kizilors; Stephen Langabeer; Benedict J Milner; Guillermina Nickless; Anna Schuh; Anne Sproul; Lihui Wang; Caroline Wickham; Nicholas C P Cross
Journal:  Br J Haematol       Date:  2011-03-08       Impact factor: 6.998

Review 5.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

6.  A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia.

Authors:  Paul A Bartley; Susan Latham; Bradley Budgen; David M Ross; Elizabeth Hughes; Susan Branford; Deborah White; Timothy P Hughes; Alexander A Morley
Journal:  J Mol Diagn       Date:  2014-12-29       Impact factor: 5.568

7.  Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns.

Authors:  C E López-Jorge; M T Gómez-Casares; A Jiménez-Velasco; M A García-Bello; M Barrios; J Lopez; S de la Iglesia; T Ramírez; G Sánchez; A I Heiniger; T Molero
Journal:  Ann Hematol       Date:  2012-04-25       Impact factor: 3.673

8.  Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?

Authors:  Jean-Michel Cayuela; Elizabeth Macintyre; Meryl Darlington; Raouf Ben Abdelali; Xavier Fund; Patrick Villarese; Michel Tulliez; Emmanuel Raffoux; François Sigaux; Delphine Réa; Valerie Seror
Journal:  Haematologica       Date:  2011-02-17       Impact factor: 9.941

9.  Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response.

Authors:  Michael E O'Dwyer; Ronan Swords; Arnon Nagler; Mary Frances McMullin; Philipp D le Coutre; Stephen E Langabeer; Alberto Alvarez-Iglesias; Hongxin Fan; Richard C Woodman; Francis J Giles; Eibhlin Conneally
Journal:  Leuk Res       Date:  2013-12-01       Impact factor: 3.156

Review 10.  Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Authors:  N C P Cross; H E White; D Colomer; H Ehrencrona; L Foroni; E Gottardi; T Lange; T Lion; K Machova Polakova; S Dulucq; G Martinelli; E Oppliger Leibundgut; N Pallisgaard; G Barbany; T Sacha; R Talmaci; B Izzo; G Saglio; F Pane; M C Müller; A Hochhaus
Journal:  Leukemia       Date:  2015-02-05       Impact factor: 11.528
  10 in total
  1 in total

1.  Authors' Reply to Crampe and Langabeer: Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.

Authors:  Elia Mattarucchi; Francesco Pallotti; Rosario Casalone
Journal:  Mol Diagn Ther       Date:  2015-08       Impact factor: 4.074
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.